Distribution of PD-L1, TROP2 and HER2- "lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation.

Maria Jose BuenoSilvana MouronEduardo CaleirasMario MartínezLuis MansoRamón ColomerMiguel Quintela-Fandino

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)

Early HER2-low, PD-L1-positive TNBC patients have a very good prognosis, particularly if treated with anthracycline/taxane- or carboplatin-containing regimes.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
open label
clinical trial
radiation therapy
squamous cell carcinoma
phase ii study
phase iii